4.12
-0.04 (-0.96%)
| Previous Close | 4.16 |
| Open | 4.17 |
| Volume | 100,039 |
| Avg. Volume (3M) | 657,430 |
| Market Cap | 90,959,168 |
| Price / Sales | 110.21 |
| Price / Book | 0.930 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Operating Margin (TTM) | -15,818.10% |
| Diluted EPS (TTM) | -7.22 |
| Total Debt/Equity (MRQ) | 352.65% |
| Current Ratio (MRQ) | 3.57 |
| Operating Cash Flow (TTM) | -111.99 M |
| Levered Free Cash Flow (TTM) | -76.86 M |
| Return on Assets (TTM) | -48.76% |
| Return on Equity (TTM) | -144.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Adverum Biotechnologies, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.10% |
| % Held by Institutions | 79.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Principia Wealth Advisory, Llc | 30 Jun 2025 | 2,029,116 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (HC Wainwright & Co., 21.36%) | Hold |
| Median | 4.50 (9.22%) | |
| Low | 4.00 (RBC Capital, -2.91%) | Hold |
| Average | 4.50 (9.22%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 4.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Nov 2025 | 5.00 (21.36%) | Hold | 4.27 |
| 23 Sep 2025 | 30.00 (628.16%) | Buy | 4.06 | |
| RBC Capital | 28 Oct 2025 | 4.00 (-2.91%) | Hold | 4.26 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |